Aquestive Therapeutics, Inc.
AQST
$2.87
$0.020.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -460.83% | -190.59% | -13.74% | 13.15% | 85.54% |
| Total Depreciation and Amortization | -45.99% | -26.14% | -34.05% | -41.73% | -46.28% |
| Total Amortization of Deferred Charges | 443.31% | 4,129.74% | 3,157.47% | 1,886.58% | 817.21% |
| Total Other Non-Cash Items | 97.30% | 231.31% | 45.52% | -31.11% | -64.58% |
| Change in Net Operating Assets | -86.43% | -205.63% | -144.81% | -120.77% | -116.70% |
| Cash from Operations | -460.49% | -590.28% | -303.39% | -289.78% | 35.02% |
| Capital Expenditure | 84.02% | 84.08% | 78.43% | -10.85% | 2.83% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 84.02% | 84.08% | 91.02% | 57.80% | 60.58% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 99.96% | -210.80% | -210.90% | -367.18% | -- |
| Issuance of Common Stock | 390.88% | 505.70% | 819.26% | 647.71% | 26.72% |
| Repurchase of Common Stock | -9,909.09% | -9,900.00% | -6,314.29% | -8,045.45% | -266.67% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.07% | 578.14% | 442.36% | 366.64% | 451.16% |
| Cash from Financing | 2,003.47% | 29,509.49% | 2,015.06% | 8,616.25% | -65.72% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,501.76% | 745.18% | 1,322.36% | 462.47% | -352.86% |